Harmony Q2 Wakix Revenue Surges 30% but CFO Transition Raises Governance Flags

What happened

Harmony Biosciences reported preliminary Q2 2026 Wakix revenue of approximately $261 million, a 30% year-over-year increase, and reaffirmed full-year guidance, indicating continued strong commercial execution. However, the announcement was accompanied by a CFO transition, which injects uncertainty into the company's financial stewardship at a critical juncture. While the revenue beat underscores WAKIX's durable growth and high-margin profile, the company has a history of EPS misses and single-asset dependence that amplifies the impact of any management shake-up. The preliminary nature of the numbers also warrants caution until audited results confirm the trend. Overall, the news supports the bull case on fundamentals but introduces a new risk factor that investors should monitor closely.

Implication

Investors should take comfort in the robust revenue growth, which reinforces the base case that WAKIX can sustain high-teens growth with expanding margins. However, the CFO transition is a red flag that could signal internal discord or a lack of confidence in the financial outlook; history shows that such transitions can sometimes precede guidance cuts or operational missteps. Given Harmony's heavy reliance on a single product, any distraction in the finance function could impair cost control and pipeline investment. The thesis remains attractive, but the risk profile has shifted slightly higher, warranting a wait-and-see approach until the company provides clarity on the CFO search and ensures a smooth handover. If the transition is handled cleanly and the new CFO brings credibility, the stock could re-rate higher; if not, the current valuation offers a smaller margin of safety.

Thesis delta

The core thesis that WAKIX can drive high-teens revenue growth and low-20% net margins is validated by the preliminary Q2 results, which came in ahead of expectations. However, the CFO transition introduces a new layer of governance and execution risk that was not prominent in the prior assessment. The investment case now hinges not only on commercial momentum but also on management's ability to navigate this transition without disrupting financial controls or strategic priorities.